Product category:
Laboratory and scientific training and education
News Release from: University of Leeds | Subject: Edict project
Edited by the Laboratorytalk Editorial
Team on 19 March 2008
Membrane expertise to seek disease
treatments
A new euro15 million project led by the University of Leeds aims to find novel treatments for many human diseases by bringing together the leading European experts in membrane proteins
The project - the European Drug Initiative for Channels and Transporters (Edict) - will target about 80 proteins, which play an important role in human diseases as varied as diabetes, heart disease, neuropsychiatric disorders like epilepsy and depression, osteoporosis, stomach ulcers and cataracts Membrane proteins are key to every process in the human body, channelling ions or transporting chemicals and so are ideal targets for new treatments
This article was originally published on Laboratorytalk on 12 Mar 2008 at 8.00am (UK)
Related stories
Microchip technology to improve disease diagnosis
The highest-density sensor array to identify multiple proteins within human blood or urine - key indicators for many human diseases - has been developed by engineers from the University of Leeds
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
Infections by pathogenic bacteria, yeasts and parasites also involve their own membrane proteins, which can be specific targets for development of new drugs and antibiotics.
The research is mainly funded by the European Commission, involves 27 partners from twelve countries - including two Nobel Laureates - and is set to last four years.
Coordinating the project is Peter Henderson, professor of biochemistry and molecular biology from Leeds's Faculty of Biological Sciences.
Further reading
Secrets of rogue cancer molecule revealed
Findings will help accelerate the search for potent and specific drugs that can target the protein and stop the growth and spread of these cancers
Another step closer to cracking cancer
The origin of a cancer which is common in people with HIV or who have had an organ transplant, Kaposi sarcoma, points way to possible future therapy
Microscopic envelopes deliver drug to tumours
Molecular envelopes could be used to deliver an anticancer drug to tumours with fewer side effects than the drug alone, a report in the British Journal of Cancer reveals this week
"Membrane proteins are seen by many as the next potential source of drug development, and so the EC is keen to fund research in this area," he said.
"However, they are difficult to study and are poorly understood, though the recent sequencing of the human and other genomes show they make up about one third of all proteins in all organisms, including humans.
"At the moment, few groups of membrane proteins are being seriously investigated by the pharmaceutical industry, so this project will help to fill that gap.
"By bringing together the best scientists in this challenging field from all over Europe, we hope to make a real advance towards new treatments for key diseases".
Industry has also seen the benefit of bringing such expertise together under one umbrella and working with the academics will be pharmaceutical giant AstraZeneca and a smaller company, Xention, which specialises in the discovery and development of novel and selective ion channel drugs.
The researchers include biologists, structural biologists, chemists and experts in the three key technologies: x-ray crystallography, nuclear magnetic resonance, and electron microscopy.
The team aims to map out the structure of the proteins, so they can identify compounds that could be developed as a treatment for these diseases.
Where they have already mapped some structures, the team will have a head start and hope to make real advances towards new treatments.
Other researchers joining the project from Leeds include professors Steve Baldwin and Carola Hunte from the Faculty of Biological Sciences and professor Peter Johnson and Colin Fishwick from the school of chemistry.
All are members of Leeds's Astbury Centre, the leading interdisciplinary research centre in the UK studying how life works at an atomic level.
The two Nobel laureates involved in the research are director of the Medical Research Council's Dunn Human Nutrition Unit in Cambridge, professor John Walker, who also holds an honorary doctorate from the University of Leeds, and director of the Max Planck Institute for Biophysics in Frankfurt, Germany, Professor Hartmut Michel.
• University of Leeds: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
